Acton, MA, United States of America

Erin O'Brien

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Kyverna Therapeutics, Inc.. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Erin O'Brien: Pioneering T-Cell Function Enhancements

Introduction: Erin O'Brien, an innovative thinker hailing from Acton, MA, has made significant contributions to the field of immunology. As a dedicated inventor, she has focused her research on advancing T-cell function, a critical area in the development of therapies for various diseases, including cancer.

Latest Patents: Erin O'Brien holds a patent for "Methods for Increasing T-Cell Function." This invention provides innovative methods aimed at enhancing T-cell efficacy and describes T-cells produced by these methods. Furthermore, it outlines therapeutic approaches using these specially produced T-cells, highlighting her impact on the medical field.

Career Highlights: Erin currently works at Kyverna Therapeutics, Inc., where she applies her expertise in immunotherapy to develop cutting-edge treatments. Her contributions to T-cell functionality play a crucial role in the company’s mission to create new and effective therapies for patients.

Collaborations: Throughout her career, Erin has collaborated with talented colleagues including John Lee and Jordan Tsai. These partnerships reflect the collaborative spirit that drives innovation in the biotechnology sector.

Conclusion: Erin O'Brien stands out as a remarkable inventor whose work on T-cell function has the potential to revolutionize therapeutic approaches in immunology. Her commitment to advancing medical science through her inventive spirit positions her as a key player in the ongoing development of impactful treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…